National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Headington, Oxford, United Kingdom.
National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Headington, Oxford, United Kingdom.
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2606-2612.e3. doi: 10.1016/j.jaip.2019.04.047. Epub 2019 May 16.
Anaphylaxis in pregnancy is an understudied, rare, and severe complication of pregnancy.
To describe the incidence and temporal trends, and to identify potential risk factors for anaphylaxis-related hospitalizations while pregnant in the United States.
All hospitalizations while pregnant and any anaphylactic reactions were identified using International Classification of Diseases, Ninth Revision, Clinical Modification codes from the National Inpatient Sample, United States, over the period 2004 to 2014. Annual incidence rates of anaphylaxis during pregnancy were calculated. Logistic regression models assessed risk factors for anaphylaxis during pregnancy, presented as odds ratios (ORs) and 95% CIs.
During the period 2004 to 2014, the incidence of anaphylaxis during pregnancy was 3.8 (95% CI, 3.4-4.2) per 100,000 hospitalizations while pregnant. The incidence did not statistically differ during the period 2004 to 2014. After adjustment, there were 3 factors that increased the odds of anaphylaxis during pregnancy: cesarean delivery (adjusted OR [aOR], 4.19; 95% CI, 3.28-5.35) compared with noncesarean delivery; history of an allergic reaction (aOR, 4.05; 95% CI, 2.64-6.23) compared with no history; and a black race (aOR, 1.57; 95% CI, 1.15-2.15) and other race (aOR, 1.69; 95% CI, 1.08-2.63) compared with white race.
Despite increased rates of cesarean delivery in the United States and consequent drug administration, there was no evidence of an increasing trend in anaphylaxis. Cesarean delivery and history of an allergic reaction allow the identification of women at risk of anaphylaxis. Not all women had clear risk factors, and preparations should always be in place to ensure timely management if this uncommon event occurs.
妊娠期间的过敏反应是一种研究较少、罕见且严重的妊娠并发症。
描述美国妊娠期间过敏反应相关住院的发生率和时间趋势,并确定其潜在的危险因素。
利用美国国家住院患者样本中国际疾病分类,第九版临床修订版代码,于 2004 年至 2014 年期间确定妊娠期间所有住院和任何过敏反应的情况。计算妊娠期间过敏反应的年发生率。采用逻辑回归模型评估妊娠期间过敏反应的危险因素,以比值比(OR)和 95%置信区间(CI)表示。
2004 年至 2014 年期间,妊娠期间过敏反应的发生率为每 100000 例妊娠住院患者 3.8 例(95%CI,3.4-4.2)。该发生率在 2004 年至 2014 年期间无统计学差异。调整后,有 3 个因素增加了妊娠期间过敏反应的可能性:与非剖宫产相比,剖宫产(调整后 OR [aOR],4.19;95%CI,3.28-5.35);与无过敏史相比,有过敏史(aOR,4.05;95%CI,2.64-6.23);与白种人相比,黑种人(aOR,1.57;95%CI,1.15-2.15)和其他种族(aOR,1.69;95%CI,1.08-2.63)。
尽管美国剖宫产率增加,相应的药物使用增加,但没有证据表明过敏反应呈上升趋势。剖宫产和过敏史可以识别有过敏反应风险的女性。并非所有女性都有明确的危险因素,如果发生这种罕见的事件,应始终做好及时管理的准备。